We recently showed that mRNA levels coding the highaffinity Fcy receptor for IgG (FcyR-I, CD64) and two of the components of the phagocytic superoxide anion-generating system-the heavy-chain subunit of cytochrome b , , , (gp91-phox) and the 47-Kd cytosolic factor (p47-phox)-are modulated by interferon gamma (IFN-y). In this study, we examined whether dexamethasone (DEX) affects gp9l-phox and p47-phox mRNA expression of human polymorphonuclear leukocytes (PMN), treated or not with IFN-y. We also investigated whether staurosporine, a general inhibitor of protein kinases, influences gp9l-phox, p47-phox, and FcyR-l gene expression in PMN treated with or without IFN-y. We found that (1) gp9l-phox mRNA steady-state levels, expressed in control or IFN-ytreated PMN, were significantly inhibited, in a dose-dependent fashion, by both DEX and staurosporine; (2) p47-phox mRNA steady-state levels, expressed in control NTERFERON-GAMMA (IFN-y) is a cytokine that I exhibits pleiotropic actions on cells of different lineage, by inducing changes in cellular enzymatic activities, as well as new mRNA and protein synthesis.' Some evidence demonstrates that IFN-y can be considered a "neutrophilactivating factor."' IFN-y is able, in fact, to increase the expression of polymorphonuclear leukocytes (PMN) plasma membrane antigens, such as the high-affinity receptor for IgG (FcyR-I or CD64)3.5 or CR3: to enhance NADPH oxidase capability to generate toxic oxygen metabolites in response to different stimuli,6 and to kill eukaryotic cells.4
I exhibits pleiotropic actions on cells of different lineage,
by inducing changes in cellular enzymatic activities, as well as new mRNA and protein synthesis.' Some evidence demonstrates that IFN-y can be considered a "neutrophilactivating factor."' IFN-y is able, in fact, to increase the expression of polymorphonuclear leukocytes (PMN) plasma membrane antigens, such as the high-affinity receptor for IgG (FcyR-I or CD64)3.5 or CR3: to enhance NADPH oxidase capability to generate toxic oxygen metabolites in response to different stimuli, 6 and to kill eukaryotic cells. 4 Recently, we observed that IFN-y specifically affects the expression of genes coding those molecules that are involved in the phenomena of PMN activation. Accumulation of mRNA transcripts encoding for the FcyR-I and the heavy-chain subunit of cytochrome b,,, (gp91-phox), a component of NADPH oxidase, were found to be increased by IFN-y within 90 minutes.738 By contrast, the mRNA expression of the 47-Kd NADPH oxidase cytosolic factor (p47-phox), was found to be downmodulated.n Furthermore, Pan et alY demonstrated that dexamethasone (DEX) inhibits the IFN-y-dependent augmentation of FcyR-I expression in PMN, with a mechanism occurring, in part, at the mRNA level. This latter observation indicated that signal transduction pathways sensitive to glucocorticoids are important for the regulation of PMN gene expression.
In this work, we wanted to determine whether DEX alters gp91-phox and p47-phox mRNA expression in PMN, when cultured in the absence or presence of IFN-y. Then, we investigated the effect of staurosporine, a nonspecific inhibitor of protein kinases," on the constitutive and IFN-y-dependent expression of FcyR-I, gp91-phox, and p47-phox mRNA steady-state levels.
We found that DEX inhibits the constitutive and IFN-ydependent gp91-phox mRNA expression, without affecting that of p47-phox. Staurosporine decreases both the two NADPH oxidase genes and IFN-y-induced FcyR-I mRNA. 
FcyR-I.
Our results demonstrate that the constitutive expression and the responsiveness to IFN-y of the genes under observation are governed by several distinct intracellular events. In addition, they highlight that gp91-phox and p47-phox genes are, in part, regulated through mechanisms completely independent from each other. highest reagent grade and were dissoved in clinical pyrogen-free water." PMN were isolated from bu@ coats of healthy donors. Briefly, blood was diluted with phosphatebuffered saline (PBS), centrifuged two times over Ficoll-Hypaque gradient, and the PMN cell pellet subjected to dextran sedimentation and erythrocyte lysis." The purity of PMN isolated by this method was always greater than 99%. as determined by WrightGiemsa and nonspecific esterase staining. PMN were suspended in RPMI-1640 medium supplemented with 10% fetal bovine serum (FCS), antibiotics, and 2 mmol/L glutamine, and incubated in polystyrene tissue culture flasks (Nunc, Roskilde, Denmark) at 37°C in 95% air/5% CO, humidified atmosphere. rlFN-y (2 ng/mL) was added after a 15-to 20-min preincubation of PMN with the different inhibitors.
Norrhem blor analysis. Total cellular RNA was isolated, analyzed, and quantitated as previously described in detail." FcyR-I, gp91-phox, p47-phox, p22-phox (the light-chain subunit of NADPH oxidase cytochrome bYsxr and actin mRNAs were detected by autoradiography after hybridization of the filters with denaturated "P-labeled (Multiprime kit; Amersham, Bucks, UK) cDNA fragments."
After an incubation for 20 hours with or without rIFN-y in the presence or absence of the various inhibitors, PMN (0.5 x 10'/50 +L distributed in roundbottom, 96-well microtiter plates) were washed and treated (30 to 60 minutes at 4°C) with appropriate dilutions of the different MoAbs (in the presence of 5% human serum, except when B137.17 analyzed. As previously shown,7" such treatment with IFN-y increases gp91-phox, decreases p47-phox, and induces FcyR-I messages. The Northern blot analysis in Fig 1A shows that DEX downregulates gp91-phox mRNA transcripts both in control and in IFN-y-treated PMN, but it does not influence p47-phox message expression in either conditions. It can also be observed that neither IFN-y7 or DEX modulates p22-phox mRNA. Finally, as previously reported: the steady-state of accumulation of FcyR-I message is less when cells are treated with glucorticoid and IFN-y. Densitometric quantification of the blots shown in Fig 1B shows that the inhibition exerted by DEX on the IFN-y-increased gp91-phox and the IFN-y-induced FcyR-I mRNA expression is dose-dependent. In all the subsequent experiments, we used 1 pmol/L DEX, because inhibition on IFN-y-induced FcyR-I expression was already maximal (see below) and cell viability was not altered at this dose. Analysis of the effect of DEX in PMN cultivated for longer than 3 hours was then performed. Densitometric evaluation of the Northern blots shown in Fig 2A demon- strates that inhibition on gp91-phox mRNA expression by DEX is already maximal after 3 hours. Inhibition by DEX on IFN-y-induced FcyR-I mRNA, although evident at all time points examined, is variable (Fig 2B) . In addition, no significative modulatory effect on p47-phox and on p22-phox mRNA expression is observed in cells treated with DEX from 3 to 20 hours, whether or not IFN-y is present. Figures 2 and 3 show that rIFN-y exerts a biphasic effect on p47-phox mRNA steady-state levels. In PMN treated with rIFN-y for 2 to 5 hours, the levels of p47-phox mRNA are lower than those of control cells (Fig 1) . In cells treated with rIFN-y for longer times, p47-phox mRNA levels are higher than those in untreated cells. This pattern results also from the fact that in untreated PMN, as previously mentioned," the expression of constitutive p47-phox message spontaneously decreases as the time passes. It can be noted that, as reported: gp91-phox mRNA levels are instead continuously increased by IFN-y.
TIME (h)
Effect of DEX on the stability of FcyR-I and gp9I-phox mRNAs in PMN treated with rIFN-y. To examine whether a change in mRNA stability was responsible for the suppressive effect of DEX on IFN-y-induced FcyR-I or IFN-y-increased gp91-phox mRNAs, PMN were incubated for 3 hours with the cytokine, with or without DEX. After that, 5 pg/mL actinomycin D was added to stop further RNA synthesis and total RNA was extracted at different times. Northern blot analysis of the experiment shown in Fig 4 shows that the decay of FcyR-I, gp91-phox, and, as expected, p47-phox mRNA transcripts in IFN-y-treated PMN is not changed by the presence of DEX. No deteriora- Effect of staurosporine on m RNA steady-state levels encoding NADPH oxidase components and FcyR-I in human PMN treated with or without rlFN-y. Northern blots in Fig 5A show the results of a representative experiment in which PMN were treated with different concentrations of staurosporine for 15 minutes and then incubated for a further 3 hours with or without rIFN-y. Densitometric quantification of the blots (Fig 5B) indicates that staurosporine exerts a dose-dependent inhibition on gp91-phox and p47-phox mRNA steady-state levels of control PMN, and on gp91-phox and FcyR-I transcripts in IFN-y-treated cells. Interestingly, staurosporine potentiates the downmodulatory effect of IFN-y on p47-phox transcripts and, as observed with DEX, it does not change p22-phox mRNA expression (densitometry not shown).
Effect of DEX and staurosporine on the induction of FcyR-I protein expression by IFN-y. Expression of FcyR-I on PMN treated for 20 hours with rIFN-y and/or increasing concen-A IFNy -+ ---+ + trations of DEX (Fig 6) or staurosporine (Fig 7) , was studied by indirect immunofluorescence analysis. Surface FcyR-I is barely detected on PMN, but it is markedly induced by rIFN-y (Figs 6A and 7A). DEX does not induce surface FcyR-I by itself (Fig 6B) , but inhibits, dosedependently, the induction of FcyR-I mediated by IFN-y (Fig 6C) . The average of FcyR-I inhibition exerted by 1 Fmol/L DEX was 52.5% 2 12.5% (n = 5). At these doses, DEX alone exerts a positive effect on CR3 expression ( Fig  6E) ; this proves the specificity of DEX inhibition on Figure 7C shows that staurosporine also inhibits the induction of FcyR-I expression mediated by IFN-y. Concentrations of staurosporine greater than 10 nmol/L were required to obtain an effect on IFN-y-induced FcyR-I expression, as well as on FcyR-I message accumulation (see above). In these experimental conditions, control and IFN-y-dependent CR3 are markedly increased by staurosporine (Fig 7E and F, respectively) . metric measurements of the phagocytic cytochrome bSS8, obtained with PMN incubated for 20 hours with rIFN-y with or without DEX and lysed with Triton X-100. As expected, the content of cytochrome b,,, of rIFN-y-treated PMN was found to be similar to that of control cells,13 and neither DEX nor 100 nmol/L staurosporine (data not shown) influenced the levels of the cromophore, regardless of the presence of rIFN-y.
DISCUSSION
PMN capability to produce toxic oxygen-derived metabolites and to express surface FcyR-I molecules can be upregulated by IFN-Y.~-~ At the molecular level, immune interferon specifically modulates the gene expression of FcyR-I and some NADPH oxidase components, namely gp91-phox and p47-pho~.~<' However, the signal transduction pathways that regulate PMN gene expression are poorly defined.
Glucocorticoids are among the most potent and widely used antiinflammatory agents.I4 They presumably decrease the formation of proinflammatory prostaglandins and lypoxygenase products or perhaps induce specific regulatory genes or proteins." Recently, it was also shown that DEX inhibits the IFN-y induction of FcyR-I antigen' and mRNAy expression in PMN.
In this study, we demonstrate that, in human PMN, constitutive and IFN-y-dependent expression of the mRNAs coding gp91-phox are markedly decreased by DEX. On the other hand, the mRNAs coding p47-phox and p22-phox were not influenced by DEX. These results suggest that gene expression of the three NADPH oxidase components investigated here is in part regulated by mechanisms that are independent from each other. This same conclusion was also obtained when the effects of LPS on gp91-phox and p47-phox mRNAs were compared with those of IFN-y.* Because glucocorticoids have been reported to decrease neutrophilI6 and macrophage capability to release hydrogen per~xide,'~ we are currently investigating whether the effects of DEX on the oxidase gene expression, described in this work, are accompanied by parallel changes of the respective protein levels and activities.
We also found that the drug exerts a concentration-and time-dependent inhibitory effect on IFN-y-induced FcyR-I mRNA and protein expression, in agreement with previous reports.'" Our data thus show that IFN-y can influence PMN gene expression through signaling pathways that differ in their sensitivity to DEX.
To elucidate what molecular mechanisms might mediate the inhibition of DEX on IFN-y-increased gp91-phox and IFN-y-induced FcyR-I mRNA expression, we investigated possible posttranscriptional effects on the stability of those messages. Compared with PMN treated with rIFN-y only, no appreciable changes of the FcyR-I and gp91-phox mature message decay were detected in cells pretreated with DEX before rIFN-y addition. Thus, specific effects in the trascriptional activity of FcyR-I and gp91-phox genes probably account for the inhibitory action of the glucocorticoid. The inhibitory effect of DEX on the steady-state levels of FcyR-I mRNA in PMN do not occur if DEX is added 90 minutes after IFN-y, and are blocked by cycloheximide (unpublished observations, June 1991). This suggests that DEX-induced proteins are involved in the regulation of FcyR-I. Other investigators have obtained similar results with U937 cells?
No studies about the involvement of protein kinases as relevant second messengers crucial for the modulation of gene expression in PMN have been so far published. We thus decided to investigate whether staurosporine, a potent nonspecific inhibitor of protein kinases,'" influences NADPH oxidase components and FcyR-I gene expression of PMN. We found that a 3-hour treatment with staurosporine suppressed the PMN constitutive and IFN-y-increased gp91-phox mRNA steady-state levels in a dose-dependent fashion, without affecting p22-phox transcripts. Also, the levels of IFN-y-induced Fcy R-I mRNA and antigen expression were diminished by staurosporine at concentrations greater than 10 nmol/L. These same effects were obtained with H7 (data not shown), a putative protein kinase C (PKC) antagonist." Unlike DEX, staurosporine significantly decreased p47-phox transcripts in control PMN, and even enhanced the negative effect exerted by rIFN-y on this message. These latter results strenghten the evidence that, in PMN, gp91-phox, p22-phox, and p47-phox gene expressions are regulated by different and separate mechanisms. Although the use of inhibitors are limited by the possibility that these agents have nonspecific actions on the cell, our data could indicate that continuous protein phosphorylation by protein kinases is required for the maintainance of constitutive gp91-phox and p47-phox mRNAs. Furthermore, de novo protein phosphorylation appears to be a necessary step for the upregulatory action of IFN-y on FcyR-I and gp91-phox mRNAs.
Despite the fact that both DEX and staurosporine decrease gp91-phox mRNA levels already after 3 hours of PMN treatment, they do not change the total amount of spectrophotometric cytochrome b,,,, even after 20 hours of incubation and independently from the presence of IFN-y (Fig 7) ." These observations suggest that, although the spectrophotometric determination does not necessarily reflect the concentration of the gp91-phox protein, the levels of cytochrome b,,, already present in PMN before addition of IFN-y or the various inhibitors are very stable and are not influenced by modifications of gp91-phox mRNA.
Another interesting finding that emerged from our study is the biphasic behavior of p47-phox mRNA in response to rIFN-y. We confirmed that a treatment of PMN for 3 hours with IFN-y downmodulates p47-phox mRNA steady-state levels8 Exposure of PMN to rIFN-y for longer than 5 hours results in higher expression of p47-phox mRNA compared with that of untreated PMN. However, in control cells, there is a spontaneous diminution of p47-phox transcripts. Whether this finding is important for responsiveness of PMN, it certainly necessitates more experiments. Recently, Abramnson et al" showed that the loss of superoxidegenerating activity and the loss of immunochemically detectable p47-phox in cultured human monocytes is prevented by the addition of IFN-y. Thus, the measurement of p47-phox protein levels in PMN at 4 and 20 hours could be important. However, one should consider that optimal activation of PMN capability to release toxic oxygen metabolites by IFN-y occurs after 3 to 4 hours." Therefore, we cannot exclude that rIFN-y activates PMN and macrophages with different mechanisms.
In conclusion, our studies Suggest that an active regulation of constitutive mRNA expression occurs in human PMN, and that multiple second messenger pathways control the modulatory effects of IFN-y on PMN genes. For personal use only. on November 15, 2017. by guest www.bloodjournal.org From
